Avicanna's CBD Cream Shows Promise for Epidermolysis Bullosa Patients

A retrospective observational study found Avicanna's RHO Phyto Ultra CBD Topical Cream improved wound healing by 55% and reduced itch scores by 65% in epidermolysis bullosa patients. The study, led by Dr. Elena Pope, evaluated the cream's efficacy and tolerability in 20 patients with an average age of 17.3 years.

author-image
Trim Correspondents
New Update
Avicanna's CBD Cream Shows Promise for Epidermolysis Bullosa Patients

Avicanna's CBD Cream Shows Promise for Epidermolysis Bullosa Patients

A retrospective observational study led by Dr. Elena Pope at The Hospital for Sick Children in Toronto has found promising results for Avicanna's RHO Phyto Ultra CBD Topical Cream in treating patients with epidermolysis bullosa (EB). The study evaluated the efficacy and tolerability of the 3% CBD cream in 20 EB patients with an average age of 17.3 years.

The results showed a 55% improvement in wound healing and a 65% reduction in itch scores after one month of daily application of the cream. Additionally, 45% of patients displayed wound stability, and 50% reported improvements in pain scores. "The use of RHO Phyto branded Ultra CBD Topical Cream is a novel topical therapeutic option for EB patients, providing symptom relief and potentially aiding in wound healing with good tolerability. Further prospective studies are needed to substantiate these findings," said Dr. Pope.

Why this matters: This study's findings have significant implications for the treatment of epidermolysis bullosa, a rare and debilitating condition with limited treatment options. The potential for CBD-based creams to provide symptom relief and improve wound healing could lead to improved quality of life for patients with EB and potentially pave the way for further research into the therapeutic applications of cannabinoids.

Epidermolysis bullosa is a rare group of inherited diseases that cause fragile skin, leading to blistering and tearing. The estimated incidence and prevalence of EB in the United States are 19 per million live births and 8 per million, respectively. Currently, there is no cure or well-accepted disease-modifying treatments for EB, and treatment is palliative, aiming to promote patient well-being, optimize wound healing, and monitor for secondary complications.

The study participants had various subtypes of EB, including dystrophic (60%), simplex (30%), and junctional (10%). Notably, 45% of patients continued to use the treatment for over 6 months. Karolina Urban, PhD, Executive Vice President of Medical Affairs at Avicanna Inc., expressed enthusiasm for the study's early positive results, stating, "We are pleased to see the Study reporting early positive results for RHO Phyto branded Ultra CBD Topical Cream in a patient population that continues to seek treatment for its catastrophic condition."

Avicanna Inc., a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, developed the RHO Phyto branded Ultra CBD Topical Cream as an oil-based, 3% CBD localized cream to target dermatology conditions. The study results will be presented at Avicanna's symposium on May 13th by Dr. Camila Sofia Arriaga Egnen from The Hospital for Sick Children.

The retrospective observational study led by Dr. Pope provides encouraging evidence for the potential of Avicanna's RHO Phyto Ultra CBD Topical Cream in managing symptoms and promoting wound healing in patients with epidermolysis bullosa. With a 55% improvement in wound healing, 65% reduction in itch scores, and 50% of patients reporting pain relief, the CBD cream offers a novel therapeutic option for this rare and debilitating condition.

Key Takeaways

  • Avicanna's CBD cream shows 55% improvement in wound healing for epidermolysis bullosa patients.
  • The cream reduces itch scores by 65% and pain scores by 50% after one month.
  • 45% of patients displayed wound stability and continued treatment for over 6 months.
  • The study's results provide a novel therapeutic option for this rare and debilitating condition.
  • Further prospective studies are needed to substantiate the findings and explore CBD's therapeutic potential.